Trump Administration Pushes for Legislative Drug Pricing Reform
Washington D.C. – The White House is actively working to translate its voluntary drug pricing agreements with pharmaceutical companies into formal legislation. Officials are currently sharing draft legislative text with over a dozen major pharmaceutical companies, signaling a continued commitment to lowering prescription drug costs.
Building on Voluntary Agreements
The proposed legislation closely mirrors the framework of the deals already struck with companies like Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. These initial agreements focused on linking U.S. Drug prices to those paid in other developed nations – a “most favored nation” (MFN) policy. The new legislative text aims to codify this approach and expand its reach.
Cash Payments and Deductibles: A Key Component
A significant element of the draft legislation involves allowing payments made in cash for prescriptions to count towards a patient’s annual deductible. This provision could incentivize patients to seek lower cash prices, potentially increasing competition and driving down overall costs. Currently, many insurance plans do not credit cash payments towards deductibles.
Broader Healthcare Reform Efforts
The push for drug pricing legislation is part of a larger effort by the Trump administration to achieve comprehensive healthcare reform. With an election year underway, the President is prioritizing affordability initiatives, elevating the profile of these efforts. This suggests a strategic move to address a key voter concern.
Nine Additional Pharma Companies Join the Effort
In December 2025, President Trump announced agreements with nine additional biopharmaceutical companies: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These companies have committed to lowering prices on drugs treating conditions like type two diabetes, rheumatoid arthritis, and certain cancers.
Tariff Relief as Incentive
A key incentive for pharmaceutical companies to participate in these agreements is a three-year grace period from potential pharmaceutical-specific tariffs. The administration has used the threat of tariffs as leverage to secure price concessions. Companies are also committing to invest at least $150 billion collectively in U.S. Manufacturing.
Strategic API Reserve Strengthened
Three of the companies involved in the drug pricing deals – Amgen, Bristol Myers Squibb, and Boehringer Ingelheim – are donating active pharmaceutical ingredients (APIs) for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This aims to reduce reliance on foreign nations and ensure a stable supply of essential medications within the United States.
Impact on Medicaid Programs
The agreements will provide access to MFN drug prices on products made by the nine companies to every State Medicaid program, potentially resulting in billions of dollars in savings for the program and its beneficiaries.
Future Trends and Implications
The move towards legislative action suggests a long-term strategy to reshape the pharmaceutical pricing landscape. Further developments could include:
Increased Transparency
Pressure for greater transparency in drug pricing is likely to continue. Legislative efforts may focus on requiring pharmaceutical companies to disclose more information about their pricing decisions and research and development costs.
Expansion of MFN Pricing
The MFN policy could be expanded to cover a wider range of drugs and potentially applied to other healthcare services.
Continued Use of Tariff Leverage
The administration may continue to use the threat of tariffs as a negotiating tactic to secure lower drug prices from companies that are reluctant to participate in voluntary agreements.
FAQ
Q: What is the “most favored nation” (MFN) pricing policy?
A: It aims to link U.S. Drug prices to the lowest prices paid in other developed nations.
Q: How will the cash payment provision affect patients?
A: It could allow patients who pay cash for prescriptions to apply those payments towards their annual deductibles.
Q: What is the role of tariffs in these agreements?
A: Pharmaceutical companies receive a three-year grace period from potential tariffs in exchange for agreeing to lower drug prices and invest in U.S. Manufacturing.
Q: Which companies have reached agreements with the Trump administration?
A: Agreements have been reached with AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
Did you know? Approximately 30% to 40% of drugs sold to Medicaid currently have prices higher than those paid in other nations.
Pro Tip: Patients should always compare prices at different pharmacies and explore available discount programs to find the lowest possible cost for their medications.
Stay informed about the latest developments in healthcare policy. Explore our other articles on drug pricing and healthcare reform to gain a deeper understanding of these complex issues.
